{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T19:55:25Z","timestamp":1648670125268},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40261-018-0738-x","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T03:57:58Z","timestamp":1547092678000},"page":"105-107","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Nuggehally R.","family":"Srinivas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"738_CR1","unstructured":"Sensipar\u00ae (cinacalcet) tablets. Highlights of prescribing information. Amgen, initial approval 2004. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021688s017lbl.pdf\n                    \n                  . Accessed 8 Oct 2018."},{"issue":"3","key":"738_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.jrn.2006.04.010","volume":"16","author":"PU Torres","year":"2006","unstructured":"Torres PU. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr. 2006;16(3):253\u20138.","journal-title":"J Ren Nutr."},{"key":"738_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1525-139X.2011.00935.x","volume":"24","author":"JR Stubbs","year":"2011","unstructured":"Stubbs JR, Wetmore JB. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? Semin Dial. 2011;24:298\u2013306.","journal-title":"Semin Dial."},{"issue":"5","key":"738_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","volume":"48","author":"D Padhi","year":"2009","unstructured":"Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303\u201311.","journal-title":"Clin Pharmacokinet."},{"issue":"2","key":"738_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00228-006-0129-8","volume":"63","author":"RZ Harris","year":"2007","unstructured":"Harris RZ, Salfi M, Posvar E, Hoelscher D, Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007;63(2):159\u201363.","journal-title":"Eur J Clin Pharmacol."},{"issue":"6","key":"738_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2165\/00003088-200746060-00003","volume":"46","author":"RZ Harris","year":"2007","unstructured":"Harris RZ, Salfi M, Sullivan JT, Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet. 2007;46(6):495\u2013501.","journal-title":"Clin Pharmacokinet."},{"issue":"10","key":"738_CR7","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1177\/0091270007304103","volume":"47","author":"D Nakashima","year":"2007","unstructured":"Nakashima D, Takama H, Ogasawara Y, Kawakami T, Nishitoba T, Hoshi S, et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J Clin Pharmacol. 2007;47(10):1311\u20139.","journal-title":"J Clin Pharmacol."},{"issue":"10","key":"738_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s40261-018-0687-4","volume":"38","author":"T Akizawa","year":"2018","unstructured":"Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M, Evocalcet Study Group. Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human phase I study. Clin Drug Investig. 2018;38(10):945\u201354.","journal-title":"Clin Drug Investig."},{"issue":"2","key":"738_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00003495-200565020-00007","volume":"65","author":"JA Barman Balfour","year":"2005","unstructured":"Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs. 2005;65(2):271\u201381.","journal-title":"Drugs."},{"key":"738_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12588","author":"K Narushima","year":"2018","unstructured":"Narushima K, Maeda H, Shiramoto M, Endo Y, Ohtsuka S, Nakamura H, et al. Assessment of CYP-mediated drug interactions for evocalcet, a new calcimimetic agent, based on in vitro investigations and a cocktail study in humans. Clin Transl Sci. 2018. \n                    https:\/\/doi.org\/10.1111\/cts.12588\n                    \n                  .","journal-title":"Clin Transl Sci."},{"issue":"10","key":"738_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CPAA.S171044","volume":"11","author":"T Shigematsu","year":"2018","unstructured":"Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Clin Pharmacol. 2018;11(10):101\u201311. \n                    https:\/\/doi.org\/10.2147\/CPAA.S171044\n                    \n                  .","journal-title":"Clin Pharmacol."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0738-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0738-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0738-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:13:14Z","timestamp":1578615194000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0738-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0738-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"10 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received to prepare this letter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The author has no conflict of interest to declare in the contents of the manuscript, which was solely prepared to exchange clinical pharmacology-related thoughts on a topic of considerable interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}